Skip to main content
. Author manuscript; available in PMC: 2015 May 27.
Published in final edited form as: Cancer. 2009 Feb 1;115(3):551–560. doi: 10.1002/cncr.24066

Table 6.

Grade 3 or 4 Adverse Events That Increased in Frequency After Imatinib Dose Escalation to >600 mg for 28 Days (July 31, 2004 Cutoff)

AEs Percentage of Patients (No.)
All Patients
During Study,
N5551		 Before Increase
to ≥600 mg
Daily, N5551		 After Increase
to ≥600 mg
Daily, N567/After
Increase to
≥800 mg Daily, N540
Nonhematologic AEs
    Fluid retention 2.2 2 1.5
    Other fluid retention 1.1 1.1 1.1
    Superficial edema 1.1 0.9 1.5
    Headache 0.5 0.4 1.5
    Abdominal pain 3.6 3.1 4.5
    Hemorrhage 1.6 1.3 3
    GI hemorrhage 0.5 0.2 3
    Pyrexia 0.9 0.7 1.5
Grade 3 or 4 hematologic AEs
    Anemia 4 (22) 3.1 (17) 7.5 (5)/7.5(3)
    Thrombocytopenia 9.3 (51) 8.2 (45) 10.4 (7)/10 (4)

AEs indicates adverse events; GI, gastrointestinal.